| FISV |
Report |
Adjusted revenue |
IN-LINE |
pred ~$5.00B vs. cons $4.99B |
MEDIUM |
| FISV |
Report |
Adjusted EPS |
BEAT |
pred ~$1.98 vs. cons $1.95 |
MEDIUM |
| FISV |
Report |
Adjusted operating margin |
IN-LINE |
pred ~33.2% vs. cons 33.0% |
MEDIUM |
| FISV |
Guide |
Organic revenue growth |
UNCHANGED |
guide ~2.0% midpoint (1%-3%) vs. cons 1.7% (FY2026) |
MEDIUM |
| FISV |
Guide |
Adjusted EPS |
UNCHANGED |
guide ~$8.15 midpoint ($8.00-$8.30) vs. cons $8.14 (FY2026) |
MEDIUM |
| FISV |
Guide |
Adjusted operating margin |
UNCHANGED |
guide ~34.0% vs. cons 33.9% (FY2026) |
MEDIUM |
| FISV |
Guide |
Adjusted revenue growth |
UNCHANGED |
guide ~7.0% midpoint (6%-8%) vs. cons 6.7% (2H2026) |
LOW |
| FISV |
Return |
Day-1 residual (stock − beta × S&P 500) |
+6.5% |
— |
LOW |
| FISV |
Return |
5-day cumulative residual |
+3.2% (FADE) |
A controlled trough quarter, modest EPS upside and reaffirmed guidance should drive an initial relief rally, but the gain should partially fade because the 2H2026 acceleration remains back-end-loaded and execution-dependent; limited estimate increases beyond 2026 constrain follow-through. |
LOW |